09 July 2026 : Clinical Research
Preliminary Application of Antihypertensive Gene Detection in the Treatment of Hypertension
Dongde Xie ABCDEFG 1*, Mingming Deng ABCDEFG 1, Xiaoming Yang ABCDEFG 1, Jie Huang ABCDEFG 1, Xucan Hong ABCDEFG 1, Ning Xu ABCDEFG 1DOI: 10.12659/MSM.952296
Med Sci Monit 2026; 32:e952296
Table 5 Prescription patterns of major antihypertensive drug classes during the study period.
| Antihypertensive drug class | Study group (n=450) | Control group (n=450) | P value |
|---|---|---|---|
| 190 (42.2%) | 198 (44.0%) | 0.621 | |
| – Benazepril | 85 (44.7% of ACEI users) | 92 (46.5% of ACEI users) | 0.712 |
| – Enalapril | 72 (37.9% of ACEI users) | 70 (35.4% of ACEI users) | 0.653 |
| – Other ACEIs (fosinopril, ramipril, etc.) | 33 (17.4% of ACEI users) | 36 (18.2% of ACEI users) | 0.852 |
| 205 (45.6%) | 195 (43.3%) | 0.524 | |
| – Losartan | 88 (42.9% of ARB users) | 95 (48.7% of ARB users) | 0.245 |
| – Valsartan | 75 (36.6% of ARB users) | 68 (34.9% of ARB users) | 0.691 |
| – Other arbs (irbesartan, candesartan, etc.) | 42 (20.5% of ARB users) | 32 (16.4% of ARB users) | 0.302 |
| 220 (48.9%) | 215 (47.8%) | 0.752 | |
| – Metoprolol | 125 (56.8% of Beta-blocker users) | 130 (60.5% of Beta-blocker users) | 0.482 |
| – Bisoprolol | 65 (29.5% of Beta-blocker users) | 58 (27.0% of Beta-blocker users) | 0.572 |
| – Other beta-blockers (carvedilol, etc.) | 30 (13.6% of Beta-blocker users) | 27 (12.6% of Beta-blocker users) | 0.723 |
| 238 (52.9%) | 232 (51.6%) | 0.712 | |
| – Amlodipine | 150 (63.0% of CCB users) | 145 (62.5% of CCB users) | 0.912 |
| – Nifedipine | 55 (23.1% of CCB users) | 58 (25.0% of CCB users) | 0.665 |
| – Other CCBs (felodipine, etc.) | 33 (13.9% of CCB users) | 29 (12.5% of CCB users) | 0.695 |
| 165 (36.7%) | 158 (35.1%) | 0.638 | |
| – Hydrochlorothiazide | 120 (72.7% of diuretic users) | 115 (72.8% of diuretic users) | 0.991 |
| – Other diuretics (indapamide, etc.) | 45 (27.3% of diuretic users) | 43 (27.2% of diuretic users) | 0.983 |
| ≥ | 385 (85.6%) | 378 (84.0%) | 0.552 |
| 2 [1–3] | 2 [1–3] | 0.884 | |
| Percentages in the main categories (ACEIs, ARBs, etc.) are calculated as “number of users in the group divided by total patients in the group (450)”. Subcategory percentages (eg, benazepril users among all ACEI users) are calculated as number of users of that specific drug divided by total users of that drug class in the group. Most patients were on combination therapy; therefore, the sum of percentages across drug classes exceeds 100%. values were calculated using the chi-square test for categorical variables and the Mann-Whitney U test for the median number of drugs. IQR – interquartile range. | |||